Shopping Cart 0
Cart Subtotal
USD 0

Restless Legs Syndrome - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Restless Legs Syndrome-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome-Pipeline Review, H2 2018, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape.

Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling and cramping in the calf's or legs. Predisposing factor includes age. Treatment includes muscle relaxants, sleep medications and narcotic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Restless Legs Syndrome-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 1 and 3 respectively.

Restless Legs Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Restless Legs Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Restless Legs Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Restless Legs Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Restless Legs Syndrome (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Restless Legs Syndrome (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Restless Legs Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Restless Legs Syndrome-Overview

Restless Legs Syndrome-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Restless Legs Syndrome-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Restless Legs Syndrome-Companies Involved in Therapeutics Development

Bioprojet SCR

Galenica Ltd

Hisamitsu Pharmaceutical Co Inc

Merz Pharma GmbH & Co KgaA

Omeros Corp

Serina Therapeutics Inc

Restless Legs Syndrome-Drug Profiles

(cannabidiol + dronabinol)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(cannabidiol + gabapentin)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aplindore fumarate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BP-1.4979-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric carboxymaltose-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

incobotulinumtoxin A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLS-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ropinirole hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SER-214-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Restless Legs Syndrome-Dormant Projects

Restless Legs Syndrome-Discontinued Products

Restless Legs Syndrome-Product Development Milestones

Featured News & Press Releases

Oct 23, 2014: Hisamitsu Announces the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)

Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Restless Legs Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Restless Legs Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Restless Legs Syndrome-Pipeline by Bioprojet SCR, H2 2018

Restless Legs Syndrome-Pipeline by Galenica Ltd, H2 2018

Restless Legs Syndrome-Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2018

Restless Legs Syndrome-Pipeline by Merz Pharma GmbH & Co KgaA, H2 2018

Restless Legs Syndrome-Pipeline by Omeros Corp, H2 2018

Restless Legs Syndrome-Pipeline by Serina Therapeutics Inc, H2 2018

Restless Legs Syndrome-Dormant Projects, H2 2018

Restless Legs Syndrome-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Restless Legs Syndrome Therapeutic Products under Development, Key Players in Restless Legs Syndrome Therapeutics, Restless Legs Syndrome Pipeline Overview, Restless Legs Syndrome Pipeline, Restless Legs Syndrome Pipeline Assessment


Companies

Bioprojet SCR

Galenica Ltd

Hisamitsu Pharmaceutical Co Inc

Merz Pharma GmbH & Co KgaA

Omeros Corp

Serina Therapeutics Inc

Restless Legs Syndrome-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome-Pipeline Review, H2 2018, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape.

Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling and cramping in the calf's or legs. Predisposing factor includes age. Treatment includes muscle relaxants, sleep medications and narcotic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Restless Legs Syndrome-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 1 and 3 respectively.

Restless Legs Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Restless Legs Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Restless Legs Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Restless Legs Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Restless Legs Syndrome (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Restless Legs Syndrome (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Restless Legs Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Restless Legs Syndrome-Overview

Restless Legs Syndrome-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Restless Legs Syndrome-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Restless Legs Syndrome-Companies Involved in Therapeutics Development

Bioprojet SCR

Galenica Ltd

Hisamitsu Pharmaceutical Co Inc

Merz Pharma GmbH & Co KgaA

Omeros Corp

Serina Therapeutics Inc

Restless Legs Syndrome-Drug Profiles

(cannabidiol + dronabinol)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(cannabidiol + gabapentin)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aplindore fumarate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BP-1.4979-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric carboxymaltose-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

incobotulinumtoxin A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLS-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ropinirole hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SER-214-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Restless Legs Syndrome-Dormant Projects

Restless Legs Syndrome-Discontinued Products

Restless Legs Syndrome-Product Development Milestones

Featured News & Press Releases

Oct 23, 2014: Hisamitsu Announces the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)

Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Restless Legs Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Restless Legs Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Restless Legs Syndrome-Pipeline by Bioprojet SCR, H2 2018

Restless Legs Syndrome-Pipeline by Galenica Ltd, H2 2018

Restless Legs Syndrome-Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2018

Restless Legs Syndrome-Pipeline by Merz Pharma GmbH & Co KgaA, H2 2018

Restless Legs Syndrome-Pipeline by Omeros Corp, H2 2018

Restless Legs Syndrome-Pipeline by Serina Therapeutics Inc, H2 2018

Restless Legs Syndrome-Dormant Projects, H2 2018

Restless Legs Syndrome-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Restless Legs Syndrome Therapeutic Products under Development, Key Players in Restless Legs Syndrome Therapeutics, Restless Legs Syndrome Pipeline Overview, Restless Legs Syndrome Pipeline, Restless Legs Syndrome Pipeline Assessment


Companies

Bioprojet SCR

Galenica Ltd

Hisamitsu Pharmaceutical Co Inc

Merz Pharma GmbH & Co KgaA

Omeros Corp

Serina Therapeutics Inc